All News

"Patients and providers should be aware of the long-term risks of radiation exposure when weighing treatment decisions,” says Avi Baskin, MD, MPhil.

Urologist Rachel S. Rubin, MD, highlights her specialized sexual medicine practice that provides care to patients of all genders.

Due to rigorous data collection, there has been very little dropout and 3-year OS and PFS compare favorably to alternate regimens such as ipilimumab nivolumab,” says Elizabeth R. Plimack, MD, MS,

The CAR T-cell therapy IVS-3001 is being explored in patients with previously treated, locally advanced or metastatic solid tumors that are HLA-G–positive.

"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.

Yale Urology Chair Isaac Y. Kim, MD, PhD, MBA, has published his concerns surrounding interpreted results in the landmark ProtecT Study.

“Our study shows that these patients can immediately benefit from supervised exercise interventions to improve their sexual health and that exercise should be considered as an integral part of treatment for prostate cancer,” says Daniel Galvao, PhD.

The Vanquish device is currently being assessed in the VAPOR 2 trial, which is evaluating the treatment in patients with intermediate risk, localized prostate cancer.

"In the setting of BCG shortages, our patients need alternatives that do not deprive them of the chance of cure," says Ashish M. Kamat, MD, MBBS.

University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.

“Increasing the representation of physicians (or actors) who appear concordant with the target audience may be an important tool for more effective health communication strategies to mitigate health disparities," the authors write.

The approval comes after a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2023.

In this installment, sisters Amy Pearlman, MD, and Michelle Pearlman, MD, highlight Prime Institute, the practice they co-founded in South Florida.

Join Dr. Catherine Bradley, urogynecologist at the University of Iowa Hospitals and Clinics, as she discusses common types of female urinary incontinence seen in practice.

"Despite prevalent OAB symptoms, only 6% of all LUTS prescriptions in men were for OAB medications," says Sarah Neu, MD, MSd, FRCSC.

“These findings suggest that the technical advantages of precision of radiotherapy delivery afforded by MRg-A-SBRT translate to measurable clinical benefit,” wrote lead study author Jonathan E. Leeman, MD.

"The burden of preauthorization, reimbursements not keeping up with inflation, and consequently, our abilities to staff and maintain our offices and pay our employees at appropriate levels are also affecting our ability to care for patients," said urologist Ronald P. Kaufman Jr, MD.

The phase 3 ATLAS and ENVISION trials are exploring UGN-102 for intravesical solution in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

Increased precision, decreased blood loss, and less risk of infection are among the benefits of robotic-assisted surgery, according to Hackensack Meridian Health.

Although the use of immunotherapy treatments continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents is limited.

"The thing that's unique about this course, in my opinion, is that we are combining the vaginoplasty and phalloplasty discussions," says Kirtishri Mishra, MD.

The study is exploring the intravesically-delivered oncolytic immunotherapy cretostimogene grenadenorepvec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

In total, 73% of patients showed an increase in 24-hour urine volume from baseline to the end of the 1-month trial period.

Flotufolastat F 18 is now included in the NCCN prostate cancer guideline recommendations for all the same categories as the other PSMA-PET imaging agents approved by the FDA.

Pre-surgical treatment with the antibody-drug conjugate enfortumab vedotin elicited substantial antitumor activity in patients with cisplatin-ineligible muscle-invasive bladder cancer.

In total, 77.8% of Black respondents, 72.7% of Asian respondents, 57.1% of Latino respondents, and 46.5% of White respondents indicated that the racial and ethnic diversity of residents at a program influenced their decision to preference signal or sub-internship with that program.

While practice ownership has declined among physicians of all ages, the sharpest drop occurred among doctors under age 45.

The UroActive device is currently being studied in the SOPHIA study, which published initial results earlier this year.